Matica Bio and VaxDome Partner to Advance Antigen-Agnostic Antiviral-Vaccine Hybrid into Clinical Trials
核心洞察
Matica Biotechnology (搜索) and VaxDome have partnered to develop a novel antigen-agnostic antiviral-vaccine hybrid candidate targeting influenza (搜索) and other viral threats.
The hybrid platform, called zIFV (搜索), transforms a selected influenza (搜索) virus strain into a safe, intranasally delivered therapeutic without requiring advance knowledge of viral genomes or mutations.
Matica Bio will provide end-to-end process development, analytical development, and cGMP manufacturing at its College Station, Texas facility.
Matica Biotechnology (搜索), Inc. and Texas-based VaxDome Inc. (搜索) have entered into a partnership to advance VaxDome's novel antigen-agnostic antiviral-vaccine hybrid candidates toward clinical trials, the companies announced on July 6, 2026. Under the agreement, Matica Bio will provide process development, analytical development, and the production of both non-GMP and cGMP clinical materials at its purpose-built facility in College Station, Texas.
The collaboration centers on VaxDome's proprietary zIFV (搜索) platform, which takes a fundamentally different approach to antiviral protection. Rather than targeting specific viral antigens that may mutate over time, the technology rapidly transforms a selected influenza (搜索) virus strain into a safe, intranasally delivered, antigen-agnostic antiviral-vaccine hybrid. This design aims to provide broad protection against diverse known and unknown viruses without requiring characterization of viral genomes or unforeseeable mutations in advance.
"We chose Matica Bio because they can handle every step of the manufacturing process under one roof," said De-chu Christopher Tang, PhD, CEO of VaxDome. "Having development, analytical testing, and GMP production fully integrated at their Texas facility gives our team complete peace of mind as we move this candidate toward the clinic."
Platform Mechanism and Therapeutic Potential
VaxDome's zIFV (搜索) technology mobilizes rapid innate and adaptive immune responses while avoiding harmful systemic inflammation, according to the company. The platform is designed to deliver safe, effective, rapid, and economic countermeasures against complex viral challenges. Influenza (搜索) serves as one of the initial disease models for the collaboration.
Beyond infectious disease, the zIFV (搜索) platform holds potential in oncology. VaxDome reports that the technology may arrest lung cancer (搜索) in situ by rapidly generating tertiary lymphoid structures within tumors. When combined with its ability to mitigate lymphopenia, the approach could spawn new therapeutic strategies for solid tumor indications.
Manufacturing Strategy
Matica Bio will manage the entire technical transition between development phases, ensuring the final vaccine meets all safety, purity, and regulatory standards. The CDMO brings expertise across multiple virus and cell modalities including AAV, lentivirus, and oncolytic viruses, and will leverage advanced single-use technologies and inline process monitoring to deliver rapid, predictable scaling from early-stage design through to clinical production.
"VaxDome's hybrid technology is a really fresh take on how we can treat and prevent viral infections in a wide variety of disease settings including flu," said Paul Kim, CEO of Matica Bio. "Our Texas site has the right systems, advanced cell line technologies, and specialized technical staff to take this project from early process development all the way through to manufacturing the actual batches for clinical trials."
The partnership underscores Matica Bio's growing role as a CDMO partner for complex, next-generation viral vector programs spanning gene therapy, immuno-oncology, and regenerative medicine. The company's integrated framework connects U.S.-based manufacturing with international clinical ecosystems, supporting scalable pathways from translational research to global clinical expansion.